Skip to main content

Table 2 Radiogenomic features of glioma biomarkers

From: Clinical applications of artificial intelligence and radiomics in neuro-oncology imaging

  Glioma biomarker Features
1 IDH IDH mutant
 Predominantly hypoenhancing diffuse gliomas
 80% LGG and 10% GBM
 Better survival
IDH wild type
 Predominantly enhancing gliomas
 90% of GBM
 Worse survival
2 1P/19q codeletion 30% of LGG
1P/19q codeletion + IDH mutant glioma
 Defines oligodendroglioma
 “poorly circumscribed” margins
1P/19q non codeletion + / − IDH mutant glioma
 Defines astrocytoma
 “circumscribed” margins
 (T2-FLAIR mismatch) pattern
3 MGMT mutation 33–57% of diffuse glioma patients
Better prognosis
4 EGFR mutation 40% of glioblastoma patients
Splice variant (EGFRvIII)
31% of glioblastoma
  1. IDH isocitrate dehydrogenase, MGMT methylation of O-6-methylguanine-DNA-methyltransferase, EGFR epidermal growth factor receptor